Scarlet Fever |
|
|
Clinical Trial: Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue
This study is no longer recruiting patients.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Typhoid Paratyphoid Fever | Vaccine: Typhoid Vi vaccine Vaccine: Hepatitis A (control) | Phase IV |
MedlinePlus related topics: Salmonella Infections
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Active Control, Single Group Assignment, Efficacy Study
Official Title: Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam. An Evaluation of Feasibility, Public Acceptability, Effectiveness and Cost-Effectiveness in Students
Secondary Outcomes: Cost-effectiveness of vaccine; Vaccine effectivenes; Adverse events; Typhoid risk factors
Expected Total Enrollment: 100742
Study start: December 2001
Typhoid fever is a major cause of morbidity worldwide. The disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. Management of this disease is further complicated by the emergence of multi-drug resistant strains. Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons: it has been shown to have consistent efficacy results even in areas of high typhoid incidence, is given as a single dose, lacks patent protection and requires less strict cold chain requirements. A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control (Hepatitis A) was designed to determine the logistic feasibility of providing Vi vaccine under actual programmatic conditions among school students in Hue City. The vaccines used in this study are internationally produced and locally licensed.
Secondary objectives of this trial are:
- To estimate the cost-effectiveness (cost of illness, willingness to pay, vaccine delivery costs, private vaccine costs, etc) of Vi vaccination
- To determine the effectiveness of the Vi polysaccharide vaccine following routine administration of a 1-dose schedule to school students (aged >=6 years)
- To determine the safety and immunogenicity of the Vi vaccine
- To study typhoid risk factors among students
A nested, prospective matched case-control study is included in the trial in order to study typhoid risk factors among children in Hue City.
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:
- Local students whose parents/guardians provide written consent to receive Vi vaccine
- Attending any of the 66 registered schools in Hue
- Registered in the project census
- Lives in Hue City
Exclusion Criteria:
- Fever (>37.5 degrees axillary)
- Pregnancy
- Lactating
Location Information
Vietnam
National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
Canh G Do, MD, Principal Investigator, National Institute of Hygiene and Epidemiology
More Information
Publications
Acosta CJ, Galindo CM, Ochiai RL, Danovaro-Holliday MC, Page AL, Thiem VD, Park JK, Park E, Koo H, Wang XY, Abu-Elyazeed R, Ali M, Albert MJ, Ivanoff B, Pang T, Xu ZY, Clemens JD. The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia. J Health Popul Nutr. 2004 Sep;22(3):240-5.
Last Updated: August 18, 2005
Record first received: August 18, 2005
ClinicalTrials.gov Identifier: NCT00131820
Health Authority: Vietnam: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13

Not Signed In -


